Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact [email protected].
SOUTH SAN FRANCISCO, CA, December 19, 2018 - Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing. The financing was led by new investor Bain Capital Life Sciences, with participation by Surveyor Capital (a Citadel...
SAN DIEGO, November 29, 2018 – ViaCyte, Inc., a privately-held clinical stage regenerative medicine company, today announced an $80 million Series D financing led by Bain Capital Life Sciences and joined by TPG and RA Capital Management, as well as existing investor, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further...
BOSTON and NEW YORK, October 23, 2018 – Bain Capital, LP and Pfizer Inc. (NYSE: PFE) today announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three...
LOWELL, MA, May 2, 2018 – Rapid Micro Biosystems, the leading provider of automated, growth-based, rapid microbial detection technology for the healthcare product manufacturing sector, announced that it has secured $60 million in equity financing led by new investors Bain Capital Life Sciences and Xeraya Capital. The new funding round also includes a commitment from another new investor, Asahi...
EVANSTON, ILLINOIS, December 18, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding clinical-stage pipeline. The financing was led by Bain Capital Life Sciences. Additional new investors include Adage...
JENA, GERMANY, October 13, 2017 - InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced today a $ 55M Series D financing and investment round. The round was co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC and complemented by certain investment funds managed by a leading US investment...
NEW YORK, September 25, 2017 - SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its launch today with a completed $103 million Series A financing funded by Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer (NYSE:PFE) and LifeArc (formerly known as...
WOBURN, MA, September 8, 2017 – Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing. The proceeds of the financing will primarily be used to generate human proof of concept data for its lead product, RP1, in multiple tumor types. The financing will also allow the Company...
CAMBRIDGE, MA, March 30, 2017 - Solid Biosciences announced today that it has completed the initial closing of its $50 Million Series C financing, which the company will use to progress its portfolio of programs targeted at Duchenne muscular dystrophy (DMD). The round was led by RA Capital Management and Bain Capital Life Sciences, together with funds from RTW Investments, Foresite Capital,...
CAMBRIDGE, MA, March 30, 2017 - Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) (the “Company”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purchase agreement with a syndicate of current and new investors, led by Bain Capital Life Sciences, for the sale of redeemable convertible preferred stock...
Cancer survivor Hank Fitzgerald is giving back in a big way by naming @DanaFarber as a beneficiary on their living… https://t.co/ESArA73hYN
You might have experienced @CityYear as a member, but the program can be just as transformative for lifelong educat… https://t.co/16gyuaD7zK
Why I PMC, with 20-year @PanMass Living Proof rider Wayne Sula: https://t.co/ycuM9f9rFg #BainCapitalCP
If you enjoyed your @CityYear service and are considering a career in social work, check this out. You could pursue… https://t.co/dotiuCVC4v
This year's @PanMass night with the @NERevolution kicks off on September 21. Get your tickets and make a donation t… https://t.co/8SQBmzCblf
Give back to @CityYear for the 6th annual Strong Circle Day. You'll help the next generation of student mentors hel… https://t.co/ZPTb8EVRpn
Read Jeff Johnston's story: "Why I #PMC" for @PanMass: https://t.co/93WpRRhkyf #BainCapitalCP
See what @CityYear CEO and co-founder Michael Brown had to say about the power of national service in conversation… https://t.co/XZYz2U7JyY
Got baking skills? Know how to run successful events? Take your talents to the @communityserv Pie in the Sky Plann… https://t.co/V9BBEby3D7
Next week, come out to @UrbanGrape in Boston for the Friends of @RosiesPlace Summer Wine Tasting. It's July 17, and… https://t.co/N5mc133A2l